Common stock, par value $0.001 per share
- Symbol
- APRE
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Aprea Therapeutics, Inc.
APRENASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On August 28, 2026, Aprea Therapeutics, Inc. issued a press release announcing the expansion of the intellectual property portfolio for its precision oncology programs. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference.
Press release in this filing
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs →Company context
Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pursuing an approach to treating cancer that seeks to exploit vulnerabilities associated with cancer cell mutations. This approach is designed to kill tumor cells while minimizing the effect on normal, healthy cells. Aprea believes its technology has potential applications across multiple cancer types, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead program is APR-1051, an oral, small molecule inhibitor of WEE1 kinase, currently in a Phase 1 clinical trial. The Company’s second clinical-stage product candidate, ATRN-119, is a small molecule ATR inhibitor for which the Company has completed a Phase 1/2a dose-escalation study and is exploring combination approaches. For more information, please visit the Company’s website at www.aprea.com.
Current securities
Recent company filings
Registered securities in this filing
Aprea Therapeutics, Inc. · 8-K · Filed 2026-08-28
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01
Other Events.
On August 28, 2026, Aprea Therapeutics, Inc. issued a press release announcing the expansion of the intellectual property portfolio for its precision oncology programs. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference.
Filed exhibits (1)
EX-99.1 2 apre-20260828xex99d1.htm EX-99.1 Exhibit 99.1 Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents DOYLESTOWN, PA, August 28, 2026 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on its existing patent portfolio. “Our expanding patent portfolio reflects Aprea’s commitment to innovation and building a differentiated leadership position in precision medicine,” said Oren Gilad, Ph. D., President and Chief Executive Officer of Aprea. “A strong global intellectual property portfolio is a critical component of our strategy, supporting the advancement of potentially best in class oncology therapies while protecting the long-term value of our programs. We remain focused on strengthening our intellectual property position as we advance our pipeline and pursue new treatment options for patients with diffi…
Open exhibit ↗